Elsevier

European Urology

Volume 73, Issue 4, April 2018, Pages 485-487
European Urology

Platinum Opinion
PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies

https://doi.org/10.1016/j.eururo.2017.10.027Get rights and content

Section snippets

Conflicts of interest

Creation of the images in this manuscript involved the administration of 18F-DCFPyL, a PSMA-targeted PET radiotracer that is being investigated under a US Food and Drug Administration investigational new drug application (IND 121064). Martin G. Pomper is a co-inventor on a US patent covering 18F-DCFPyL, and is thus entitled to a portion of any licensing fees and royalties generated by this technology. Michael A. Gorin has served as a consultant to Progenics Pharmaceuticals, the licensee of 18

References (11)

There are more references available in the full text version of this article.

Cited by (97)

  • How to Report PSMA PET

    2024, Seminars in Nuclear Medicine
  • <sup>18</sup>F-DCFPyL PET/CT guidelines

    2023, Revista Espanola de Medicina Nuclear e Imagen Molecular
View all citing articles on Scopus
View full text